Long‐standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: A possible involvement of Th17 across the spectrum of both diseases

Yoshida, Yasuyuki; Oyama, Noritaka; Iino, Shiro; Shimizu, Chihiro; Hasegawa, Minoru

doi:10.1111/1346-8138.15807

Cited by 17 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 311 studies identified, 36 full texts were assessed for eligibility and 16 met inclusion criteria, representing 128 patients (mean age: 36.5 years; age range: 21-47 years; male: 50.0%) (Supplemental File 5-6). [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28] Studies included 9 case reports, 4 cohort studies and 3 clinical trials. Level of evidence analysis yielded 9 studies with a level of evidence of 5, 4 studies with level of evidence of 2, and 3 studies with level of evidence of 1.…”

Section: Study and Patient Characteristicsmentioning

confidence: 99%

Treatment Outcomes of IL-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

The IL-17 pathway is a potential therapeutic target shown to be implicated in hidradenitis suppurativa (HS), however, it remains unclear whether evidence from mechanistic studies may translate into clinical practice. This systematic review summarizes available treatment outcomes of IL-17 inhibitors in patients with HS. Embase, MEDLINE, PubMed, and clinicaltrials.gov were comprehensively searched on February 26, 2021 to include 16 original studies representing 128 patients with HS (mean age: 36.5 years; age range: 21-47 years; male: 50.0%). Treatment outcomes were reported for the following biologics: secukinumab ( n = 105), brodalumab ( n = 22), and ixekizumab ( n = 1). Patients were classified as responders or non-responders according to achievement of a positive response/improvement based on criteria established for each included study. For secukinumab 57.1% ( n = 60/105) of patients were responders in a mean response period of 16.2 weeks and 42.9% ( n = 45/105) were non-responders; for brodalumab, 100.0% ( n = 22/22) of patients were responders within 4.4 weeks; and the one patient treated with ixekizumab was a responder within 10 weeks. In conclusion, IL-17 inhibitors may serve as an effective therapeutic target in approximately two-thirds of patients with HS and can be considered in those who are refractory to other treatment modalities. We also stress the importance of consistent outcome measures to enhance evidence synthesis, decrease reporting bias, provide potential for future meta-analysis, and ultimately improve clinical outcomes for patients with HS.

show abstract

Section: Study and Patient Characteristicsmentioning

confidence: 99%

Treatment Outcomes of IL-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Brodalumab is typically dosed at 210 mg weekly for 2 weeks, then every 2 weeks thereafter. Three case reports utilizing this dosage regimen reported improvement of HS in all three patients, two of whom had comorbid psoriasis that improved as well 22,103,104 . An open‐label study of 10 patients using this dosing regimen achieved HiSCR in 100% of patients by Week 12 105 .…”

Section: Il‐17 Inhibitorsmentioning

confidence: 86%

Biologics and small molecule inhibitors for hidradenitis suppurativa

Shih

De²,

Shi

et al. 2022

Dermatological Reviews

View full text Add to dashboard Cite

Background: Hidradenitis suppurativa (HS) is a debilitating, chronic inflammatory dermatosis that is often recalcitrant to first-line treatments. Though mechanisms underlying its pathology remain unclear, a number of upregulated inflammatory cytokines (including tumor necrosis factor-α [TNF-α], interleukin [IL]-1, IL-17, IL-12, and IL-23) have been identified in HS, leading to a growing investigation of targeted biologic therapies in moderate-to-severe HS.Objective: We aim to review the current literature on biologics and small molecule inhibitors that have been used to treat HS and discuss mechanisms of action, dosing, safety considerations, and recommendations for use.

show abstract

“…BRO has shown promising results in three case reports, 133,150,151 and two phase I open-label trials have been conducted. An open-label cohort study included 10 patients with moderate-to-severe HS who were treated with BRO 210 mg sc at weeks 0, 1, and 2 and every 2 weeks thereafter until week 24.…”

Section: Treatmentmentioning

confidence: 99%

New perspectives on the treatment of hidradenitis suppurativa

Amat-Samaranch

Agut-Busquet

Vilarrasa

et al. 2021

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by the presence of painful nodules, abscesses, chronically draining fistulas, and scarring in apocrine gland-bearing areas of the body. The exact pathogenesis of HS is not yet well understood, but there is a consensus in considering HS a multifactorial disease with a genetic predisposition, an inflammatory dysregulation, and an influence of environmental modifying factors. Therapeutic approach of HS is challenging due to the wide clinical manifestations of the disease and the complex pathogenesis. This review describes evidence for effectiveness of current and emerging HS therapies. Topical therapy, systemic treatments, biological agents, surgery, and light therapy have been used for HS with variable results. Adalimumab is the only US Food and Drug Administration (FDA) approved biologic agent for moderate-to-severe HS, but new therapeutic options are being studied, targeting different specific cytokines involved in HS pathogenesis. Comparing treatment outcomes between therapies is difficult due to the lack of randomized controlled trials. Treatment strategy should be selected in concordance to disease severity and requires combination of treatments in most cases.

show abstract

Long‐standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: A possible involvement of Th17 across the spectrum of both diseases

Cited by 17 publications

References 15 publications

Treatment Outcomes of IL-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review

Treatment Outcomes of IL-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review

Biologics and small molecule inhibitors for hidradenitis suppurativa

New perspectives on the treatment of hidradenitis suppurativa

Contact Info

Product

Resources

About